

Practitioner's Docket No. 4389-5-C1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Guida, Marco et al.

Application No.: 10/085,612

Group No.: 1634

Filed: February 26, 2002

Examiner: Diana B. Johannsen

For: Methods for evaluating the ability to metabolize pharmaceuticals and compositions therefor

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311

whichever occurs first.

FEE


2. Accompanying this transmittal is the fee for submission of an information disclosure statement under section 1.97(c). (\$180.00), as authorized on the accompanying Fee Transmittal Form.

Date: March 8, 2004

Reg. No.: 47,934

Tel. No.: 203-786-3468

Customer No.: 25106



Signature of Practitioner

Sandra L. Shaner

Genaissance Pharmaceuticals, Inc.,

Five Science Park

New Haven, CT 06511

